Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

People who take an anticoagulant medicine double their risk of an internal bleed if they take a type of painkiller called a ...

Maxim Group analyst Naz Rahman has reiterated their bullish stance on TLPH stock, giving a Buy rating on November 14. Naz Rahman has given his ...

Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

DOACs only and warfarin only are more likely to be prescribed to Medicare beneficiaries seeing clinicians in rural areas compared with urban areas.

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific ...

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Portola has said European regulators are to review its anticoagulant antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug. California-based Portola said the ...

Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein ...